Which new approved presentations should enter the comparison?
FDA approved Wegovy tablets on December 22, 2025 and Foundayo/orforglipron tablets on April 1, 2026. These approvals expand the approved-product options for clinician-led access reviews; they do not establish clinical interchangeability, a particular clinic’s wholesale eligibility or equivalent performance of compounded oral preparations. Wegovy approval package; Foundayo approval announcement. (accessdata.fda.gov)
Recommended comparison: exact approved product and presentation, patient eligibility, pharmacy route, ongoing patient cost, fulfilment responsibilities and implementation effort. Do not compare unlike medicines as though milligrams were interchangeable purchasing units.
What is the current Medicare GLP-1 Bridge position?
Bridge is operating, and it is not a January 2027 handoff to Medicare BALANCE. CMS’s April 21, 2026 update extended Bridge through December 31, 2027 and told Part D sponsors not to indicate BALANCE participation for calendar 2027. The programme launched July 1, 2026, with a $50 monthly copay for eligible beneficiaries. CMS status update; launch announcement. (cms.gov)
CMS currently lists Foundayo tablets, Wegovy injection and tablets, and Zepbound KwikPen. Its prescriber instructions explicitly exclude Zepbound single-dose pens and vials from Bridge. Exact presentation therefore matters as much as the brand name. CMS prescriber instructions. (cms.gov)
Bridge operates outside the normal Part D coverage/payment flow. Eligibility includes clinical and coverage restrictions; for example, CMS excludes beneficiaries eligible for GLP-1 coverage for specified other conditions and applies a prior-Part-D-use screen. CMS had not specified its 2027 utilisation lookback period in the FAQ reviewed. CMS Part D FAQ. (cms.gov)
Operational acceptance test: ask the pharmacy to demonstrate eligibility screening, correct presentation selection, Bridge claim routing, receipt of the resulting prior-authorisation request, and rejected-claim follow-up. CMS instructs prescribers to include an obesity diagnosis code and a Bridge-routing note. (cms.gov)
Financial interpretation: the $50 is a qualifying patient copay, not a clinic acquisition price or margin opportunity. Keep patient expenditure, clinic service revenue and clinic operating costs in separate columns.
For Medicaid, CMS permits state entry into BALANCE from May 2026 through January 1, 2027, but coverage depends on state and manufacturer participation and does not guarantee access for an individual. Verify the relevant state programme rather than forecasting national uptake. CMS BALANCE page. (cms.gov)
Sources cited on this page
- accessdata.fda.gov · Source 1 ↗https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/218316Orig1s000Approv.pdf
- fda.gov · Source 2 ↗https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
- accessdata.fda.gov · Source 3 ↗https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/218316Orig1s000Approv.pdf?utm_source=openai
- cms.gov · Source 4 ↗https://www.cms.gov/files/document/status-update-bridge-demo-balance-model-part-d-cy2027-g-pdf.pdf
- cms.gov · Source 5 ↗https://www.cms.gov/newsroom/press-releases/cms-launches-medicare-glp-1-bridge-expanding-access-glp-1-medications
- cms.gov · Source 6 ↗https://www.cms.gov/files/document/glp-1-prescribers-c-1.pdf
- cms.gov · Source 7 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
- cms.gov · Source 8 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans?utm_source=openai
- cms.gov · Source 9 ↗https://www.cms.gov/priorities/innovation/innovation-models/balance